A recent study, published by Neurology, found that p-tau T217 has better diagnostic accuracy for detecting Alzheimer’s disease than p-tau T181. Jozef Hanes, AXON Neuroscience R&D Services SE, Bratislava, Slovakia, and colleagues write that this higher level of accuracy shows the potential for p-tau T217 assay to be used as a diagnostic test for Alzheimer’s disease at clinical evaluation.
In this novel immunoassay study, the investigators assessed whether p-tau T217 assay in cerebrospinal fluid (CSF) can distinguish Alzheimer’s disease from other dementias and healthy controls.
There were a total of 190 participants included in the study, split into three groups: those with Alzheimer’s, those with other neurodegenerative diseases, and healthy control subjects.
The p-tau T217 assay identified the subjects with Alzheimer’s 90% of the time. This is a higher level of accuracy that p-tau T181 ELISA, which has an accuracy rate of 78%, the authors report
